QuantuMDx’s anti-coagulant stratification test will provide a warfarin metabolism genotyping test at the point of care.
Our first available test will take the guess work out of warfarin dosage by identifying subsets of the population who could develop life-threatening bleeds on the standard dose.
The effectiveness of this important drug is hindered by uninformed prescriptions
Warfarin is an effective and low cost blood thinner for individuals at risk of clots, including people with atrial fibrillation, pulmonary thrombosis, deep vein thrombosis and stroke.
Warfarin is a low cost, effective and widely used anti-coagulant drug, with over 10 million prescriptions annually in the UK alone. It is used to treat patients suffering from, among other things, atrial fibrillation (AF), pulmonary thrombosis, deep vein thrombosis, post-heart attack and stroke, by effectively ‘thinning’ the blood and reducing the risk of further clots developing.
The safe and effective dosage of warfarin varies up to 20-fold between individuals. Current clinical practice sees a standard loading dose prescribed, then patient monitoring over a number of months with the dosage increased or decreased until the appropriate maintenance dose is found.
As well as the heightened risk of adverse events such as bleeding or stroke during the dosage adjustment period, this accrues cost through additional patient visits and repeated INR testing (International Normalised Ratio, which checks how long it takes blood to clot).
The first point of care warfarin dose prediction test.
Our first commercially available test will take the guess work out of warfarin dosage, giving clinicians the information they need to quickly determine a safe and effective dose for their patient.
This test features three single nucleotide polymorphisms (SNPs) which, when integrated into an algorithm, inform an individual’s warfarin requirements.
QuantuMDx’s warfarin sensitivity test will provide a genotyping test at the point of care. This assay will determine the patient’s variants of VKORC1, CY2C9*2 and CYP2C9*3 and is designed to assist a clinical professional in deciding which anticoagulant drug and at which dose is best for that patient. Test results will include the genotypes and interpretation guidance.